New Drugs

Breakthrough GLP‑1/GIP Dual Agonist “Tirzepatide”: The Next Generation in Type 2 Diabetes and Obesity Treatment

Introduction: Why Tirzepatide Is Dominating Diabetes and Obesity Research Tirzepatide has rapidly become one of the most talked‑about new drug substances in metabolic disease. As a first‑in‑class dual GLP‑1/GIP receptor agonist, it represents a major step forward beyond traditional GLP‑1 analogues used for type 2 diabetes and obesity. Early and late‑stage clinical data show unprecedented…